Literature DB >> 33431783

Non-Alcoholic Fatty Liver Disease Is Strongly Associated with Smoking Status and Is Improved by Smoking Cessation in Japanese Males: A Retrospective Study.

Haruka Takenaka1, Tsuyoshi Fujita2, Atsuhiro Masuda1, Yoshihiko Yano1, Akihiko Watanabe3, Yuzo Kodama1.   

Abstract

BACKGROUND: Cigarette smoking is known to be a significant risk factor associated with non-alcoholic fatty liver disease (NAFLD). We aimed to examine the association between smoking status and the severity of fatty liver with regard to sex and smoking cessation.
METHODS: In total, 13,466 subjects (6,642 males and 6,824 females) who had undergone abdominal ultrasonography for health check-up, multivariable logistic regression analysis was retrospectively conducted to assess the association between smoking status and the prevalence of NAFLD stratified by sex after adjusting for other potential confounders.
RESULTS: Male sex (odds ratio [OR] 3.27, 95% confidence interval [CI] 3.00-3.57) and smoking history (former smoker: OR 1.23, 95% CI 1.10-1.38, current smoker: OR 1.31, 95% CI 1.17-1.47) were significantly associated with NAFLD. In males with a smoking history, an increased pack-year was strongly associated with the prevalence and severity of NAFLD (prevalence of moderate to severe fatty liver: Pack-year from 0.01 to 9.99, 21.3%; Pack-year from 10.00 to 19.99, 27.2%; Pack-year ≥20.00, 33.7%; P<0.0001), although the prevalence of moderate to severe fatty liver was inversely associated with the duration of smoking cessation (more than 10 years vs. within 5 years, OR 0.71, 95% CI 0.53-0.96). In female subjects, light current smoking was negatively associated with NAFLD (current smoker with a pack-year from 0.01 to 9.99 vs. never smoker, OR 0.41, 95% CI 0.19-0.76).
CONCLUSIONS: Smoking status and pack-year were strongly associated with the prevalence and severity of NAFLD, especially in Japanese males. However, smoking cessation improved NAFLD in this population.

Entities:  

Keywords:  Non-alcoholic fatty liver disease; sex difference; smoking cessation; smoking status

Year:  2020        PMID: 33431783      PMCID: PMC7837663     

Source DB:  PubMed          Journal:  Kobe J Med Sci        ISSN: 0023-2513


  31 in total

Review 1.  Metabolic effects of smoking cessation.

Authors:  Kindred K Harris; Mohan Zopey; Theodore C Friedman
Journal:  Nat Rev Endocrinol       Date:  2016-03-04       Impact factor: 43.330

2.  Studies in the distribution of body fat. III. Effects of cigarette smoking.

Authors:  H Shimokata; D C Muller; R Andres
Journal:  JAMA       Date:  1989-02-24       Impact factor: 56.272

3.  Association between cotinine-verified smoking status and risk of nonalcoholic fatty liver disease.

Authors:  Nam Hee Kim; Yoon Suk Jung; Hyun Pyo Hong; Jung Ho Park; Hong Joo Kim; Dong Il Park; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim
Journal:  Liver Int       Date:  2018-02-17       Impact factor: 5.828

4.  Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study.

Authors:  Hyun-Suk Jung; Yoosoo Chang; Min-Jung Kwon; Eunju Sung; Kyung Eun Yun; Yong Kyun Cho; Hocheol Shin; Seungho Ryu
Journal:  Am J Gastroenterol       Date:  2019-03       Impact factor: 10.864

5.  What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?

Authors:  Jian-Gao Fan; Toshiji Saibara; Shivakumar Chitturi; Byong Ik Kim; Joseph J Y Sung; A Chutaputti
Journal:  J Gastroenterol Hepatol       Date:  2007-05-13       Impact factor: 4.029

Review 6.  Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World.

Authors:  Mehmet Sayiner; Aaron Koenig; Linda Henry; Zobair M Younossi
Journal:  Clin Liver Dis       Date:  2015-12-14       Impact factor: 6.126

7.  Insulin resistance and cigarette smoking.

Authors:  F S Facchini; C B Hollenbeck; J Jeppesen; Y D Chen; G M Reaven
Journal:  Lancet       Date:  1992-05-09       Impact factor: 79.321

8.  Lifetime cigarette smoking is associated with abdominal obesity in a community-based sample of Japanese men: The Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA).

Authors:  Akira Fujiyoshi; Katsuyuki Miura; Sayaka Kadowaki; Koichiro Azuma; Sachiko Tanaka; Takashi Hisamatsu; Hisatomi Arima; Aya Kadota; Naoko Miyagawa; Naoyuki Takashima; Takayoshi Ohkubo; Yoshino Saitoh; Sayuki Torii; Itsuko Miyazawa; Hiroshi Maegawa; Kiyoshi Murata; Hirotsugu Ueshima
Journal:  Prev Med Rep       Date:  2016-06-16

9.  Active smoking, passive smoking, and risk of nonalcoholic fatty liver disease (NAFLD): a population-based study in China.

Authors:  Yu Liu; Meng Dai; Yufang Bi; Min Xu; Yu Xu; Mian Li; Tiange Wang; Fei Huang; Baihui Xu; Jie Zhang; Xiaoying Li; Weiqing Wang; Guang Ning
Journal:  J Epidemiol       Date:  2013-02-09       Impact factor: 3.211

10.  Association between smoking and non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Arash Akhavan Rezayat; Malihe Dadgar Moghadam; Mohammad Ghasemi Nour; Matin Shirazinia; Hamidreza Ghodsi; Mohammad Reza Rouhbakhsh Zahmatkesh; Mitra Tavakolizadeh Noghabi; Benyamin Hoseini; Kambiz Akhavan Rezayat
Journal:  SAGE Open Med       Date:  2018-01-24
View more
  2 in total

1.  Croton urucurana Baill. Ameliorates Metabolic Associated Fatty Liver Disease in Rats.

Authors:  Pablo Alvarez Auth; Gustavo Ratti da Silva; Eduarda Carolina Amaral; Victor Fajardo Bortoli; Mariana Inocencio Manzano; Lauro Mera de Souza; Evellyn Claudia Wietzikoski Lovato; João Tadeu Ribeiro-Paes; Arquimedes Gasparotto Junior; Francislaine Aparecida Dos Reis Lívero
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

2.  Gut bacteria alleviate smoking-related NASH by degrading gut nicotine.

Authors:  Bo Chen; Lulu Sun; Guangyi Zeng; Zhe Shen; Kai Wang; Limin Yin; Feng Xu; Pengcheng Wang; Yong Ding; Qixing Nie; Qing Wu; Zhiwei Zhang; Jialin Xia; Jun Lin; Yuhong Luo; Jie Cai; Kristopher W Krausz; Ruimao Zheng; Yanxue Xue; Ming-Hua Zheng; Yang Li; Chaohui Yu; Frank J Gonzalez; Changtao Jiang
Journal:  Nature       Date:  2022-10-19       Impact factor: 69.504

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.